Amarin Announces Promotion of Aaron Berg to Position of Chief Commercial Officer
April 23 2018 - 5:00AM
Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical
company focused on the commercialization and development of
therapeutics to improve cardiovascular (CV) health, today announced
that Aaron Berg has been promoted to the position of Senior Vice
President, Chief Commercial Officer. Mr. Berg previously served the
company as Senior Vice President, Marketing and Sales. Mr. Berg
joined Amarin in November of 2012 and has played a leading role in
U.S. prescription and related revenue growth of the company’s lead
product, Vascepa® (icosapent ethyl) capsules.
Mr. Berg is an industry veteran. Before joining
Amarin, Mr. Berg served as President and Chief Executive Officer
for Essentialis, Inc., a development stage pharmaceutical company
where he led the company's work on triglyceride management. Prior
to joining Essentialis, Mr. Berg served as Vice President of
Marketing and Sales at Kos Pharmaceuticals (Kos), where he was
instrumental in driving annual revenues approaching $1
billion. Mr. Berg worked at Kos until it was acquired by
Abbott Laboratories in December 2006 for $3.7 billion. Mr. Berg
began his pharmaceutical industry career as a sales representative
with Bristol-Myers Squibb, followed by various commercial positions
with Schering-Plough and GlaxoSmithKline.
In this expanded role, Mr. Berg will be
responsible for ensuring continued commercial growth for Vascepa
based on its current indication while preparing for and ensuring
successful expanded promotion of Vascepa assuming positive results
of the company’s landmark REDUCE-IT cardiovascular outcomes trial.
The results of this important study are anticipated before
the end of Q3 2018. The company thanks Mark Salyer, whose
position is being filled by Mr. Berg, for his ideas and
contributions and wishes him much success in his future
endeavors.
"Aaron has made invaluable contributions to
Amarin over multiple years,” said John F. Thero, President and
Chief Executive Officer of Amarin. “He has wide-ranging experience
and comprehensive knowledge of our industry combined with an
entrepreneurial spirit and a collaborative approach which makes him
broadly respected and well-positioned to help lead Amarin in
fulfilling our commercial opportunities. We are excited to work
with Aaron in this important leadership position.”
About Vascepa® (icosapent ethyl)
capsules
Vascepa® (icosapent ethyl) capsules are a
single-molecule prescription product consisting of the omega-3 acid
commonly known as EPA in ethyl-ester form. Vascepa is not fish oil,
but is derived from fish through a stringent and complex
FDA-regulated manufacturing process designed to effectively
eliminate impurities and isolate and protect the single molecule
active ingredient. Vascepa is also known in scientific literature
as AMR101. Amarin has been issued multiple patents
internationally based on the unique clinical profile of Vascepa,
including the drug’s ability to lower triglyceride levels in
relevant patient populations without raising LDL-cholesterol
levels.
FDA-Approved Indication and Usage
- Vascepa (icosapent ethyl) is indicated as an adjunct to diet to
reduce triglyceride (TG) levels in adult patients with severe (≥500
mg/dL) hypertriglyceridemia.
- The effect of Vascepa on the risk for pancreatitis and
cardiovascular mortality and morbidity in patients with severe
hypertriglyceridemia has not been determined.
Important Safety Information for Vascepa
- Vascepa is contraindicated in patients with known
hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of
its components.
- Use with caution in patients with known hypersensitivity to
fish and/or shellfish.
- The most common reported adverse reaction (incidence > 2%
and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0%
for placebo). There was no reported adverse reaction > 3% and
greater than placebo.
- Patients receiving treatment with Vascepa and other drugs
affecting coagulation (e.g., anti-platelet agents) should be
monitored periodically.
- In patients with hepatic impairment, monitor ALT and AST levels
periodically during therapy.
- Patients should be advised to swallow Vascepa capsules whole;
not to break open, crush, dissolve, or chew Vascepa.
- Adverse events and product complaints may be reported by
calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
FULL VASCEPA PRESCRIBING INFORMATION CAN BE
FOUND AT WWW.VASCEPA.COM.
Vascepa has been approved for use by the United
States Food and Drug Administration (FDA) as an adjunct to diet to
reduce triglyceride levels in adult patients with severe (≥500
mg/dL) hypertriglyceridemia. Vascepa is under various stages of
development for potential use in other indications that have not
been approved by the FDA. Nothing in this press release should be
construed as promoting the use of Vascepa in any indication that
has not been approved by the FDA.
About Amarin
Amarin Corporation plc is a biopharmaceutical
company focused on the commercialization and development of
therapeutics to improve cardiovascular health. Amarin's
product development program leverages its extensive experience in
lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Amarin's clinical program
includes a commitment to an ongoing cardiovascular outcomes
study. Vascepa® (icosapent ethyl), Amarin's first
FDA-approved product, is a highly-pure, omega-3 fatty acid product
available by prescription. For more information about Vascepa
visit www.vascepa.com. For more information about Amarin
visit www.amarincorp.com.
Forward-looking
statements
This press release contains forward-looking
statements, including expectations for continued commercial growth
and revenue levels, results and related timing and announcements
with respect to Amarin's REDUCE-IT cardiovascular outcomes study;
expectations related to the final outcomes of the REDUCE-IT study
and the anticipated successful completion of the REDUCE-IT study;
and statements regarding the potential and therapeutic benefits of
Vascepa and the significance of patents. These forward-looking
statements are not promises or guarantees and involve substantial
risks and uncertainties. In particular, as disclosed in filings
with the U.S. Securities and Exchange Commission, Amarin's ability
to effectively develop and commercialize Vascepa will depend in
part on its ability to continue to effectively finance its
business, efforts of third parties, its ability to create market
demand for Vascepa through education, marketing and sales
activities, to achieve increased market acceptance of Vascepa, to
receive adequate levels of reimbursement from third-party payers,
to develop and maintain a consistent source of commercial supply at
a competitive price, to comply with legal and regulatory
requirements in connection with the sale and promotion of Vascepa
and to maintain patent protection for Vascepa. Among the factors
that could cause actual results to differ materially from those
described or projected herein include the following: uncertainties
associated generally with research and development, clinical trials
and related regulatory approvals; the risk that regulatory reviews
may alter current expectations; the risk that future legal
determinations and interactions with regulatory authorities may
impact Vascepa marketing and sales rights and efforts; the risk
that Vascepa may not show clinically meaningful effects in
REDUCE-IT or support regulatory approvals for cardiovascular risk
reduction; and the risk that patents may not adequately protect
Vascepa against competition. A further list and description
of these risks, uncertainties and other risks associated with an
investment in Amarin can be found in Amarin’s filings with the U.S.
Securities and Exchange Commission, including its most recent
Annual Report on Form 10-K. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date
hereof. Amarin undertakes no obligation to update or revise
the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise.
Availability of other information about
Amarin
Investors and others should note that we
communicate with our investors and the public using our company
website (www.amarincorp.com), our investor relations website
(http://investor.amarincorp.com), including but not limited to
investor presentations and investor FAQs, Securities and Exchange
Commission filings, press releases, public conference calls and
webcasts. The information that we post on these channels and
websites could be deemed to be material information. As a
result, we encourage investors, the media, and others interested in
Amarin to review the information that we post on these channels,
including our investor relations website, on a regular basis.
This list of channels may be updated from time to time on our
investor relations website and may include social media
channels. The contents of our website or these channels, or
any other website that may be accessed from our website or these
channels, shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933.
Amarin contact information:
Investor Relations:Elisabeth Schwartz Investor Relations and
Corporate Communications Amarin Corporation plc In U.S.: +1
(908) 719-1315 investor.relations@amarincorp.com Lee M. Stern Trout
Group In U.S.: +1 (646) 378-2992
lstern@troutgroup.com
Media Inquiries: Kristie Kuhl Finn Partners In U.S.: +1
(212) 583-2791 Kristie.kuhl@finnpartners.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024